PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.49%
R&D reduction while TRVN shows 11.53% growth. Joel Greenblatt would examine competitive risk.
-16.18%
G&A reduction while TRVN shows 16.84% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
-22.68%
Operating expenses reduction while TRVN shows 14.31% growth. Joel Greenblatt would examine advantage.
-22.68%
Total costs reduction while TRVN shows 14.31% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
7.12%
D&A growth while TRVN reduces D&A. John Neff would investigate differences.
22.73%
EBITDA growth exceeding 1.5x TRVN's 4.64%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
22.68%
Operating income growth exceeding 1.5x TRVN's 11.33%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
26.92%
Other expenses growth while TRVN reduces costs. John Neff would investigate differences.
22.99%
Pre-tax income growth exceeding 1.5x TRVN's 5.12%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Tax expense growth while TRVN reduces burden. John Neff would investigate differences.
22.99%
Net income growth while TRVN declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
38.32%
EPS growth exceeding 1.5x TRVN's 4.30%. David Dodd would verify competitive advantages.
38.32%
Diluted EPS growth exceeding 1.5x TRVN's 4.30%. David Dodd would verify competitive advantages.
24.80%
Share count reduction below 50% of TRVN's 7.90%. Michael Burry would check for concerns.
24.80%
Diluted share reduction below 50% of TRVN's 7.90%. Michael Burry would check for concerns.